
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
Joseph Hill, MA, director of federal legislative affairs for ASHP, describes the key issues that health-system pharmacists will face in 2015.
Joseph Hill, MA, director of federal legislative affairs for ASHP, describes the key issues that health-system pharmacists will face in 2015.
This interview was recorded at the ASHP 2014 Midyear Clinical Meeting in Anaheim, California.






